1
|
Escudero-Cabarcas J, Pineda-Alhucema W, Martinez-Banfi M, Acosta-López JE, Cervantes-Henriquez ML, Mejía-Segura E, Jiménez-Figueroa G, Sánchez-Barros C, Puentes-Rozo PJ, Noguera-Machacón LM, Ahmad M, de la Hoz M, Vélez JI, Arcos-Burgos M, Pineda DA, Sánchez M. Theory of Mind in Huntington's Disease: A Systematic Review of 20 Years of Research. J Huntingtons Dis 2024; 13:15-31. [PMID: 38517797 DOI: 10.3233/jhd-230594] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/24/2024]
Abstract
Background People with Huntington's disease (HD) exhibit neurocognitive alterations throughout the disease, including deficits in social cognitive processes such as Theory of Mind (ToM). Objective The aim is to identify methodologies and ToM instruments employed in HD, alongside relevant findings, within the scientific literature of the past two decades. Methods We conducted a comprehensive search for relevant papers in the SCOPUS, PubMed, APA-PsyArticles, Web of Science, Redalyc, and SciELO databases. In the selection process, we specifically focused on studies that included individuals with a confirmed genetic status of HD and investigated ToM functioning in patients with and without motor symptoms. The systematic review followed the PRISMA protocol. Results A total of 27 papers were selected for this systematic review, covering the period from 2003 to 2023. The findings consistently indicate that ToM is globally affected in patients with manifest motor symptoms. In individuals without motor symptoms, impairments are focused on the affective dimensions of ToM. Conclusions Based on our analysis, affective ToM could be considered a potential biomarker for HD. Therefore, it is recommended that ToM assessment be included as part of neuropsychological evaluation protocols in clinical settings. Suchinclusion could aid in the identification of early stages of the disease and provide new opportunities for treatment, particularly with emerging drugs like antisense oligomers. The Prospero registration number for this review is CRD42020209769.
Collapse
Affiliation(s)
- Johana Escudero-Cabarcas
- Centro de Inv. e Innovación en Ciencias Sociales, Facultad de ciencias jurídicas y Sociales, Universidad Simón Bolívar, Barranquilla, Colombia
| | - Wilmar Pineda-Alhucema
- Centro de Inv. e Innovación en Ciencias Sociales, Facultad de ciencias jurídicas y Sociales, Universidad Simón Bolívar, Barranquilla, Colombia
| | - Martha Martinez-Banfi
- Centro de Inv. e Innovación en Ciencias Sociales, Facultad de ciencias jurídicas y Sociales, Universidad Simón Bolívar, Barranquilla, Colombia
| | - Johan E Acosta-López
- Centro de Inv. e Innovación en Ciencias Sociales, Facultad de ciencias jurídicas y Sociales, Universidad Simón Bolívar, Barranquilla, Colombia
| | - Martha L Cervantes-Henriquez
- Centro de Inv. e Innovación en Ciencias Sociales, Facultad de ciencias jurídicas y Sociales, Universidad Simón Bolívar, Barranquilla, Colombia
| | - Elsy Mejía-Segura
- Centro de Inv. e Innovación en Ciencias Sociales, Facultad de ciencias jurídicas y Sociales, Universidad Simón Bolívar, Barranquilla, Colombia
| | - Giomar Jiménez-Figueroa
- Centro de Inv. e Innovación en Ciencias Sociales, Facultad de ciencias jurídicas y Sociales, Universidad Simón Bolívar, Barranquilla, Colombia
| | - Cristian Sánchez-Barros
- Hospital Juaneda Miramar Departamento de Neurofisiología Clínica Palma de Mallorca, Islas Baleares, España
| | - Pedro J Puentes-Rozo
- Centro de Inv. e Innovación en Ciencias Sociales, Facultad de ciencias jurídicas y Sociales, Universidad Simón Bolívar, Barranquilla, Colombia
- Grupo de Neurociencias del Caribe, Universidad del Atlántico, Barranquilla, Colombia
| | | | - Mostapha Ahmad
- Universidad Simón Bolívar, Facultad de Ciencias de la Salud Barranquilla, Colombia
| | - Moisés de la Hoz
- Universidad Simón Bolívar, Facultad de Ciencias de la Salud Barranquilla, Colombia
| | | | - Mauricio Arcos-Burgos
- Grupo de Investigación en Psiquiatría (GIPSI), Departamento de Psiquiatría, Instituto de Investigaciones Médicas, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia
| | - David A Pineda
- Grupo de investigación Neuropsicología y Conducta, Universidad de San Buenaventura, Medellín, Colombia
| | - Manuel Sánchez
- Centro de Inv. e Innovación en Ciencias Sociales, Facultad de ciencias jurídicas y Sociales, Universidad Simón Bolívar, Barranquilla, Colombia
| |
Collapse
|
2
|
Li F, Li K, Li C, Luo S. Predicting the Risk of Huntington's Disease with Multiple Longitudinal Biomarkers. J Huntingtons Dis 2020; 8:323-332. [PMID: 31256145 DOI: 10.3233/jhd-190345] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND Huntington's disease (HD) has gradually become a public health threat, and there is a growing interest in developing prognostic models to predict the time for HD diagnosis. OBJECTIVE This study aims to develop a novel prognostic model that leverages multiple longitudinal biomarkers to inform the risk of HD. METHODS The multivariate functional principal component analysis was used to summarize the essential information from multiple longitudinal markers and to obtain a set of prognostic scores. The prognostic scores were used as predictors in a Cox model to predict the right-censored time to diagnosis. We used cross-validation to determine the best model in PREDICT-HD (n = 1,039) and ENROLL-HD (n = 1,776); external validation was carried out in ENROLL-HD. RESULTS We considered six commonly measured longitudinal biomarkers in PREDICT-HD and ENROLL-HD (Total Motor Score, Symbol Digit Modalities Test, Stroop Word Test, Stroop Color Test, Stroop Interference Test, and Total Functional Capacity). The prognostic model utilizing these longitudinal biomarkers significantly improved the predictive performance over the model with baseline biomarker information. A new prognostic index was computed using the proposed model, and can be dynamically updated over time as new biomarker measurements become available. CONCLUSION Longitudinal measurements of commonly measured clinical biomarkers substantially improve the risk prediction of Huntington's disease diagnosis. Calculation of the prognostic index informs the patient's risk category and facilitates patient selection in future clinical trials.
Collapse
Affiliation(s)
- Fan Li
- Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA.,Duke Clinical Research Institute, Durham, NC, USA
| | - Kan Li
- Merck Research Lab, Merck & Co, North Wales, PA, USA
| | - Cai Li
- Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA
| | - Sheng Luo
- Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA.,Duke Clinical Research Institute, Durham, NC, USA
| | | |
Collapse
|
3
|
Glidden AM, Luebbe EA, Elson MJ, Goldenthal SB, Snyder CW, Zizzi CE, Dorsey ER, Heatwole CR. Patient-reported impact of symptoms in Huntington disease: PRISM-HD. Neurology 2020; 94:e2045-e2053. [PMID: 32193209 DOI: 10.1212/wnl.0000000000008906] [Citation(s) in RCA: 35] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2019] [Accepted: 11/20/2019] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE To determine the frequency and relative importance of symptoms experienced by adults with Huntington disease (HD) and to identify factors associated with a higher disease burden. METHODS We performed 40 qualitative interviews (n = 20 with HD, n = 20 caregivers) and analyzed 2,082 quotes regarding the symptomatic burden of HD. We subsequently performed a cross-sectional study with 389 participants (n = 156 with HD [60 of whom were prodromal], n = 233 caregivers) to assess the prevalence and relative importance (scale 0-4) of 216 symptoms and 15 symptomatic themes in HD. Cross-correlation analysis was performed based on sex, disease duration, age, number of CAG repeats, disease burden, Total Functional Capacity score, employment status, disease status, and ambulatory status. RESULTS The symptomatic themes with the highest prevalence in HD were emotional issues (83.0%), fatigue (82.5%), and difficulty thinking (77.0%). The symptomatic themes with the highest relative importance to participants were difficulty thinking (1.91), impaired sleep or daytime sleepiness (1.90), and emotional issues (1.81). High Total Functional Capacity scores, being employed, and having prodromal HD were associated with a lower prevalence of symptomatic themes. Despite reporting no clinical features of the disease, prodromal individuals demonstrated high rates of emotional issues (71.2%) and fatigue (69.5%). There was concordance between the prevalence of symptoms reported by manifest individuals and caregivers. CONCLUSIONS Many symptomatic themes affect the lives of those with HD. These themes have a variable level of importance to the HD population and are identified both by those with HD and by their caregivers.
Collapse
Affiliation(s)
- Alistair M Glidden
- From the Center for Health + Technology (A.M.G., C.W.S., C.E.Z., E.R.D., C.R.H.) and Department of Neurology (E.A.L., E.R.D., C.R.H.), University of Rochester Medical Center, NY; Emory School of Medicine (M.J.E.), Emory University, Atlanta, GA; and University of Michigan Medical School (S.B.G.), University of Michigan, Ann Arbor
| | - Elizabeth A Luebbe
- From the Center for Health + Technology (A.M.G., C.W.S., C.E.Z., E.R.D., C.R.H.) and Department of Neurology (E.A.L., E.R.D., C.R.H.), University of Rochester Medical Center, NY; Emory School of Medicine (M.J.E.), Emory University, Atlanta, GA; and University of Michigan Medical School (S.B.G.), University of Michigan, Ann Arbor
| | - Molly J Elson
- From the Center for Health + Technology (A.M.G., C.W.S., C.E.Z., E.R.D., C.R.H.) and Department of Neurology (E.A.L., E.R.D., C.R.H.), University of Rochester Medical Center, NY; Emory School of Medicine (M.J.E.), Emory University, Atlanta, GA; and University of Michigan Medical School (S.B.G.), University of Michigan, Ann Arbor
| | - Steven B Goldenthal
- From the Center for Health + Technology (A.M.G., C.W.S., C.E.Z., E.R.D., C.R.H.) and Department of Neurology (E.A.L., E.R.D., C.R.H.), University of Rochester Medical Center, NY; Emory School of Medicine (M.J.E.), Emory University, Atlanta, GA; and University of Michigan Medical School (S.B.G.), University of Michigan, Ann Arbor
| | - Christopher W Snyder
- From the Center for Health + Technology (A.M.G., C.W.S., C.E.Z., E.R.D., C.R.H.) and Department of Neurology (E.A.L., E.R.D., C.R.H.), University of Rochester Medical Center, NY; Emory School of Medicine (M.J.E.), Emory University, Atlanta, GA; and University of Michigan Medical School (S.B.G.), University of Michigan, Ann Arbor
| | - Christine E Zizzi
- From the Center for Health + Technology (A.M.G., C.W.S., C.E.Z., E.R.D., C.R.H.) and Department of Neurology (E.A.L., E.R.D., C.R.H.), University of Rochester Medical Center, NY; Emory School of Medicine (M.J.E.), Emory University, Atlanta, GA; and University of Michigan Medical School (S.B.G.), University of Michigan, Ann Arbor
| | - E Ray Dorsey
- From the Center for Health + Technology (A.M.G., C.W.S., C.E.Z., E.R.D., C.R.H.) and Department of Neurology (E.A.L., E.R.D., C.R.H.), University of Rochester Medical Center, NY; Emory School of Medicine (M.J.E.), Emory University, Atlanta, GA; and University of Michigan Medical School (S.B.G.), University of Michigan, Ann Arbor
| | - Chad R Heatwole
- From the Center for Health + Technology (A.M.G., C.W.S., C.E.Z., E.R.D., C.R.H.) and Department of Neurology (E.A.L., E.R.D., C.R.H.), University of Rochester Medical Center, NY; Emory School of Medicine (M.J.E.), Emory University, Atlanta, GA; and University of Michigan Medical School (S.B.G.), University of Michigan, Ann Arbor.
| |
Collapse
|
4
|
Ross CA, Reilmann R, Cardoso F, McCusker EA, Testa CM, Stout JC, Leavitt BR, Pei Z, Landwehrmeyer B, Martinez A, Levey J, Srajer T, Bang J, Tabrizi SJ. Movement Disorder Society Task Force Viewpoint: Huntington's Disease Diagnostic Categories. Mov Disord Clin Pract 2019; 6:541-546. [PMID: 31538087 PMCID: PMC6749806 DOI: 10.1002/mdc3.12808] [Citation(s) in RCA: 59] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2018] [Revised: 04/12/2019] [Accepted: 04/15/2019] [Indexed: 12/20/2022] Open
Affiliation(s)
- Christopher A. Ross
- Departments of Psychiatry, Neurology, Neuroscience, and Pharmacology and Huntington's Disease CenterJohns Hopkins University School of MedicineBaltimoreMDUSA
| | - Ralf Reilmann
- George Huntington Institut, Head, European HD Network (EHDN) Huntington CenterUniversity of MunsterMunsterGermany
| | - Francisco Cardoso
- Department of Neurology in the Movement Disorders Unit, Neurology ServiceInternal Medicine Department of the Federal University of Minas GeraisBelo HorizonteMGBrazil
| | - Elizabeth A. McCusker
- Neurology Department, Huntington Disease ServiceWestmead Hospital and Sydney University Medical SchoolSydneyAustralia
| | | | - Julie C. Stout
- Institute of Cognitive and Clinical Neurosciences, School of Psychological SciencesMonash UniversityVictoriaAustralia
| | - Blair R. Leavitt
- Department of Medical Genetics and Centre for Molecular Medicine and TherapeuticsThe University of British ColumbiaVancouverCanada
| | - Zhong Pei
- The First Affiliated HospitalSun Yat‐Sen UniversityGuangzhouChina
| | | | | | - Jamie Levey
- Cure HD Initiative (CHDI) Management/CHDI FoundationPrincetonNJUSA
- European Huntington's Disease NetworkUniversity Hospital of UlmUlmGermany
| | | | - Jee Bang
- Departments of Neurology and Psychiatry, and Huntington's Disease CenterJohns Hopkins University School of MedicineBaltimoreMDUSA
| | - Sarah J. Tabrizi
- Huntington's Disease Centre, University College LondonQueen Square Institute of NeurologyLondonUnited Kingdom
- UK Dementia Research InstituteUniversity College LondonLondonUnited Kingdom
| |
Collapse
|